Subcutaneous infusion of ND0612 (a levodopa-carbidopa solution) increases on time without troublesome dyskinesia among patients with Parkinson disease, according to a study published online March 15 ...

Learn about switching from IVIg to SCIg for CIDP, including benefits, barriers, and support for home-based subcutaneous ...

Please provide your email address to receive an email when new articles are posted on . The study examined efficacy of subcutaneous vs. oral administration of carbidopa/levodopa. Subcutaneous infusion ...

Traditionally, isotope dilution kinetic studies of glucose, FFA, and amino acid metabolism in humans have primarily used intravenous infusion (and oral administration when tracing enteral absorption) ...

Levodopa is most commonly administered orally, but this trial tested continuous, 24-hour levodopa delivery through a subcutaneous infusion pump. A total of 381 patients with Parkinson's disease in 16 ...

Please provide your email address to receive an email when new articles are posted on . 52-week study included 85 adults with Parkinson’s and at least 3 hours/day of “off” time. At week 12, CSAI led ...

BD (Becton, Dickinson and Company), a leading global medical technology company, announces the approval of the BD Saf-T-Intima™ Safety Integrated IV Catheter System for use in subcutaneous infusion ...

MILAN -- An investigational 10-minute subcutaneous injection of ocrelizumab (Ocrevus) was non-inferior to the established IV infusion formulation of the drug in multiple sclerosis (MS), the phase III ...

Allen CH, Etzwiler LS, Miller MK, et al for the Increased Flow Utilizing Subcutaneously-Enabled-(INFUSE) Pediatric Rehydration Study Collaborative Research Group Oral rehydration is the preferred ...

– Late-breaking Phase III results show subcutaneous injection was non-inferior to intravenous infusion based on Ocrevus levels in the blood over 12 weeks – – Ocrevus subcutaneous injection was ...